CytRx (NASDAQ: CYTR) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare CytRx to related companies based on the strength of its analyst recommendations, profitability, valuation, risk, dividends, institutional ownership and earnings.


This table compares CytRx and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CytRx N/A -210.45% -72.41%
CytRx Competitors -3,345.60% -538.95% -39.87%

Analyst Recommendations

This is a breakdown of current ratings for CytRx and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CytRx 0 0 2 0 3.00
CytRx Competitors 535 2403 6535 125 2.65

CytRx currently has a consensus price target of $24.00, indicating a potential upside of 1,118.27%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.38%. Given CytRx’s stronger consensus rating and higher possible upside, analysts plainly believe CytRx is more favorable than its competitors.

Insider and Institutional Ownership

45.0% of CytRx shares are owned by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 5.3% of CytRx shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares CytRx and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CytRx $200,000.00 -$50.76 million -1.13
CytRx Competitors $217.29 million -$39.39 million -63.95

CytRx’s competitors have higher revenue and earnings than CytRx. CytRx is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

CytRx has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, CytRx’s competitors have a beta of 1.53, indicating that their average stock price is 53% more volatile than the S&P 500.

CytRx Company Profile

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.

Receive News & Ratings for CytRx Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.